Michael Andria

UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan

Leslie E. Carlini, Neal J. Meropol, John L. Bever et al. · Clinical Cancer Research · 2005 · 261 citations · Full text

Medicine, Oncology, Pharmacology +17

Thymidine Phosphorylase Expression Is Associated With Response to Capecitabine Plus Irinotecan in Patients With Metastatic Colorectal Cancer

Neal J. Meropol, Philip J. Gold, Robert B. Diasio et al. · Journal of Clinical Oncology · 2006 · 110 citations

Medicine, Oncology, Pharmacology +17

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy

Eric Van Cutsem, Florence Joulain, Paulo M. Hoff et al. · Targeted Oncology · 2015 · 47 citations

Medicine, Oncology, Pharmacotherapy +17

A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD)

Wenhui Wei, Eric Ghorayeb, Michael Andria et al. · Annals of Allergy Asthma & Immunology · 2019 · 43 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma

Michael R. Migden, Sunandana Chandra, Guilherme Rabinowits et al. · Future Oncology · 2020 · 36 citations · Full text

Medicine, Oncology, Radiation Oncology +17